-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagene Doses First Patient In First-In-Human Phase 1 Study Of ADG138, Double-Masked HER2×CD3 Bispecific T-Cell Engager Built On IgG1-Based Format And Adagene’s Proprietary Safebody Precision Masking Technology

Benzinga·11/19/2026 12:11:02
Diffusion vocale

First-in-human study will enroll patients with HER2-positive advanced solid tumors

ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation

SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and Adagene’s proprietary SAFEbody® precision masking technology.